stoxline Quote Chart Rank Option Currency Glossary
  
Intensity Therapeutics, Inc. (INTS)
4.875  0.025 (0.52%)    07-19 13:15
Open: 4.78
High: 4.9
Volume: 919
  
Pre. Close: 4.85
Low: 4.78
Market Cap: 67(M)
Technical analysis
2024-07-19 1:51:15 PM
Short term     
Mid term     
Targets 6-month :  5.95 1-year :  6.95
Resists First :  5.09 Second :  5.95
Pivot price 4.88
Supports First :  4.72 Second :  4.5
MAs MA(5) :  4.87 MA(20) :  4.9
MA(100) :  4.64 MA(250) :  4.69
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  43 D(3) :  46.3
RSI RSI(14): 50.5
52-week High :  11.43 Low :  2
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ INTS ] has closed above bottom band by 47.9%. Bollinger Bands are 72.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 32 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 4.97 - 5 5 - 5.02
Low: 4.79 - 4.82 4.82 - 4.84
Close: 4.81 - 4.85 4.85 - 4.89
Company Description

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.

Headline News

Wed, 17 Jul 2024
Intensity Therapeutics Approves New Employee Stock Plan - Investing.com

Wed, 17 Jul 2024
Intensity Therapeutics Shareholders Engage and Elect at Annual Meeting - TipRanks

Tue, 09 Jul 2024
Intensity Therapeutics, Inc. Announces First Patient Dosed in its Global Randomized, Phase 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma - PR Newswire

Wed, 15 May 2024
Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors - PR Newswire

Tue, 14 May 2024
Intensity Therapeutics: A Bargain Late-Stage Company With Remarkable Oncology Drug (INTS) - Seeking Alpha

Fri, 10 May 2024
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug Candidate - PR Newswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 14 (M)
Shares Float 6 (M)
Held by Insiders 47.3 (%)
Held by Institutions 11.9 (%)
Shares Short 33 (K)
Shares Short P.Month 21 (K)
Stock Financials
EPS -1.11
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.7
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -110.5 %
Return on Equity (ttm) -734.4 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0 %
Operating Cash Flow -11 (M)
Levered Free Cash Flow -6 (M)
Stock Valuations
PE Ratio -4.44
PEG Ratio 0
Price to Book value 6.86
Price to Sales 0
Price to Cash Flow -6.27
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android